The U.S. Food and Drug Administration (FDA) has informed a federal court that it expects to complete a comprehensive safety review of the abortion pill mifepristone by March 2027. This review follows a major study involving about 200,000 women and is being closely watched as legal battles over abortion medication continue across the United States. The timeline was disclosed in a status report submitted to U.S. District Judge David Joseph in Louisiana, where state Attorney General Liz Murrill is challenging federal rules that allow abortion pills to be prescribed remotely and shipped by mail.

Explainer FDA and Mifepristone: Regulatory Battles Over Abortion Pill Access and Safety

The outcome of the FDA's review could have significant implications for how mifepristone is prescribed and distributed nationwide. This is particularly relevant in states with near-total abortion bans, where residents may still be able to access medication from out-of-state providers. The review comes at a time when Republican-led states, including Louisiana, Alabama, and Arkansas, are pursuing legal action to restrict abortion medications from crossing state lines. These states argue that mailing abortion drugs into states with bans violates their laws, even if the medication is prescribed by out-of-state providers.

Details of the FDA Review

According to the court filing, the FDA expects to receive results from its safety study by mid-December, with a final report due by March. The agency will then determine whether changes to current regulations are necessary. The study compares outcomes for approximately 100,000 women who used mifepristone with another 100,000 women in a control group. Researchers are examining adverse health events and comparing outcomes between medication abortion and surgical procedures. The FDA is utilizing the Sentinel surveillance system and a statistical method known as TreeScan to identify any previously undetected safety issues related to mifepristone use.

The agency has also received petitions urging it to reinstate the requirement that mifepristone be dispensed in person at medical facilities. These petitions cite more than 170 articles and publications and have generated hundreds of public comments, according to the court filing. The FDA is reviewing these materials as part of its ongoing evaluation.

Mifepristone, when used in combination with misoprostol, has been approved by the FDA for abortion since 2000. Over the years, the agency has repeatedly found the drug to be safe and effective, with serious complications considered rare. Major medical organizations, including the American College of Obstetricians and Gynecologists, oppose restrictions on mifepristone that they consider medically unnecessary.

In 2023, the FDA under then-President Joe Biden removed the in-person dispensing requirement, allowing certified pharmacies to provide mifepristone. Louisiana's lawsuit contends that the FDA did not adequately assess the risks associated with loosening these restrictions. The legal challenge argues that permitting remote prescription and mail delivery of abortion pills increases the risk of adverse outcomes and undermines state laws banning abortion.

Judge Joseph declined to immediately block the FDA's regulations in April, instead pausing the lawsuit to allow the agency to finish its review. He wrote that Louisiana was likely to succeed in its challenge but said that allowing the FDA to complete its work "would better serve the public interest."

"Only then will the agency determine whether changes to its existing regulations are necessary."

β€” U.S. Food and Drug Administration, court filing

Following Judge Joseph's decision, Louisiana appealed, and the 5th U.S. Circuit Court of Appeals ordered the 2023 rules suspended in May. However, the U.S. Supreme Court later blocked that decision, keeping mail-order access to mifepristone available while litigation continues. This means that, for now, patients in states where abortion is legal can still receive mifepristone by mail, even as court challenges proceed.

Broader State Efforts and Responses

The dispute in Louisiana is part of a broader campaign by Republican-led states to limit access to abortion medication. In addition to Louisiana, states such as Alabama and Arkansas have filed lawsuits against out-of-state providers, arguing that shipping abortion pills into states with bans is illegal. These legal efforts reflect a growing trend among states seeking to enforce their abortion laws beyond their borders, especially following the Supreme Court's decision to overturn Roe v. Wade in 2022.

Supporters of the FDA's current rules, including major medical organizations, argue that restrictions on mifepristone are not supported by scientific evidence and would limit access to safe and effective care. They maintain that the FDA's review process is thorough and that the agency should be allowed to complete its evaluation before any regulatory changes are considered.

The FDA has not indicated whether it will recommend changes to its regulations before the March deadline. The agency's final decision will likely influence ongoing legal battles and could set new standards for how abortion medication is accessed in the United States. As the review continues, both sides of the debate are closely monitoring developments, recognizing that the outcome could reshape the landscape of abortion access for years to come.